Tuesday, May 21, 2019 12:56:57 PM
Naerodynamics Announces Plans to Update Filings on Pinksheets and Remove Caveat Emptor
Press Release Source: NaeroDynamics, Inc. On Tuesday March 9, 2010, 11:57 am EST
CHICAGO, IL--(Marketwire - 03/09/10) - Telecom circuit cost management specialists IE Telco Solutions (IETS), a wholly owned subsidiary of NaeroDynamics, Inc. (Pinksheets:NDYN - News), announces that they are preparing the necessary filing required by Pinksheets.com to remove the caveat emptor status and begin upgrading their transparency tiers.
"We have immediate plans to begin the process of becoming fully compliant with Pinksheets.com required disclosure statement tiers," stated Lee Wiskowski and Doug Stukel, co-CEOs of the Illinois based holding company NaeroDynamics, Inc. "As well, we plan on beginning to provide the market with regular forms of corporate communications, so that our core shareholders and potential new investors can begin to monitor all our recent progress and make informed decisions on our next series of pending material developments.
About Us:
IE Telco Solutions Ltd (IETS), a wholly owned subsidiary of NaeroDynamics, Inc., specializes in managing and reducing telecoms circuit costs for Telcos and large enterprise. The Company offers a powerful combination of highly skilled and experienced telecoms professionals combined with a unique software application Enterprise Circuit Manager (ECM). ECM ensures full circuit lifecycle inventory control, significant data quality improvements, supplier invoice reconciliation, network optimization, and proven cost reduction. www.ietelcosolutions.com
Forward-Looking Statements:
Certain information discussed in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the company's inability to accurately forecast its operating results; the company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the company's business. For further information on factors which could impact the company and the statements contained herein, reference should be made to the company's filings with the Securities and Exchange Commission, including annual reports on Form 10-KSB, quarterly reports on Form 10-QSB and current reports on Form 8-K. The company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.
Then the shell was bought by David Cutler who along with JWM and others created Vortex Tennis. Another failure!
And now this.
Recent COEP News
- Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 • PR Newswire (US) • 05/08/2024 12:47:00 PM
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting • PR Newswire (US) • 05/02/2024 12:47:00 PM
- Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award • PR Newswire (US) • 04/02/2024 12:47:00 PM
- Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections • PR Newswire (US) • 02/07/2024 12:30:00 PM
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 • PR Newswire (US) • 10/31/2023 01:01:00 PM
- Coeptis Therapeutics Announces $2 Million Private Placement • PR Newswire (US) • 10/24/2023 12:30:00 PM
- Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology • PR Newswire (US) • 10/11/2023 11:30:00 AM
- Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 01:15:00 PM
- Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting • PR Newswire (US) • 10/04/2023 11:30:00 AM
- Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa • PR Newswire (US) • 09/27/2023 11:30:00 AM
- Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection • PR Newswire (US) • 09/14/2023 11:30:00 AM
- Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment • PR Newswire (US) • 09/11/2023 11:30:00 AM
- Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer • PR Newswire (US) • 08/30/2023 05:00:00 PM
- Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics • PR Newswire (US) • 08/17/2023 11:30:00 AM
- Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic • PR Newswire (US) • 08/01/2023 12:00:00 PM
- Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering • PR Newswire (US) • 06/16/2023 08:00:00 PM
- Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering • PR Newswire (US) • 06/14/2023 01:28:00 PM
- Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market • PR Newswire (US) • 06/09/2023 11:00:00 AM
- Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer • PR Newswire (US) • 05/17/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM